Inventions, Government-owned; availability for licensing,

[Federal Register: January 11, 2006 (Volume 71, Number 7)]

[Notices]

[Page 1793]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr11ja06-74]

DEPARTMENT OF VETERANS AFFAIRS

Office of Research and Development

Government Owned Invention Available for Licensing

AGENCY: Office of Research and Development, VA.

ACTION: Notice of Government owned invention available for licensing.

SUMMARY: The invention listed below is owned by the U.S. Government as represented by the Department of Veterans Affairs, and is available for licensing in accordance with 35 U.S.C. 207 and 37 CFR part 404 and/or Cooperative Research and Development Agreements (CRADA) Collaboration under 15 U.S.C. 3710a to achieve expeditious commercialization of results of federally funded research and development. Foreign patents are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Technical and licensing information on the invention may be obtained by writing to: Amy E. Centanni, Department of Veterans Affairs, Director, Technology Transfer Program, Office of Research and Development, 810 Vermont Avenue, NW., Washington, DC 20420; fax: 202-254-0473; e-mail at amy.centanni@mail.va.gov. Any request for information should include

the Number and Title for the relevant invention as indicated below. Issued patents may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.

SUPPLEMENTARY INFORMATION: The invention available for licensing is:

U.S. Patent No. 6,770,622 ``N-Terminally Truncated Galectin-3 for use in Treating Cancer.''

Dated: December 27, 2005. Gordon H. Mansfield, Deputy Secretary of Veterans Affairs.

[FR Doc. 06-214 Filed 1-10-06; 8:45 am]

BILLING CODE 8320-01-M

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT